Drug Profile
Depemokimab - GSK
Alternative Names: AQ82742999; GSK 294; GSK-3511294Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Asthma; Churg-Strauss syndrome; Hypereosinophilic syndrome; Rhinosinusitis
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Asthma in Germany (SC, Controlled release)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Asthma in United Kingdom (SC, Controlled release)
- 23 Dec 2022 GlaxoSmithKline completes a phase I trial (In volunteers) for Asthma in China (SC, Injection) (NCT05140200)